---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-385225"
form_type: "8-K"
ticker: "BBOT"
cik: "0001869105"
company_name: "BridgeBio Oncology Therapeutics, Inc."
filed_at: "2026-09-08T20:19:06+00:00"
generated_at: "2026-09-08T20:20:23.428227+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BBOT reports 75% ORR for BBO-8520 combo in 2L+ NSCLC; focuses on KRAS combos

## Summary
- BBO-8520 + pembrolizumab: 75% ORR at 500 mg QD, 53% across doses in 2L+ G12C inhibitor-experienced NSCLC (N=17).
- BBO-8520 monotherapy ORR 63% (26/41), DCR 100% (41/41), no grade 3 liver enzyme elevations in 2L+ G12C inhibitor-naive NSCLC.
- $344.1M cash as of June 30, 2026; projected runway into 2028.
- Strategic focus on BBO-8520 combo and BBO-11818/BBO-10203 combos in KRAS-mutant CRC and PDAC; data updates Q4 2026 and mid-2027.

## SEC filing metadata
- accession: 0001193125-26-385225
- form_type: 8-K
- ticker: BBOT
- cik: 0001869105
- company_name: BridgeBio Oncology Therapeutics, Inc.
- filed_at: 2026-09-08T20:19:06+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1869105/000119312526385225/0001193125-26-385225-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1869105/000119312526385225/d97546d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-385225
- JSON: https://secwatch.observer/filing/0001193125-26-385225.json
- Plain text: https://secwatch.observer/filing/0001193125-26-385225.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.